Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | The future of SAGE-718 in Alzheimer’s disease treatment

SAGE-718 is an investigational drug that has shown positive results in its initial Phase II clinical trial (NCT04602624). In 26 patients with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD) who received SAGE-718 daily for two weeks, an overall trend of improved cognitive performance was observed across all tests of executive functioning. Aaron Koenig, MD, Sage Therapeutics Inc., Cambridge, MA, discusses the future of SAGE-718 in the AD treatment landscape. Dr Koenig stresses that given the heterogeneity of AD risk factors and outcomes, treatments need to be individualized to each patient. However, cognitive decline and its impact on day-to-day function is common amongst AD patients. The improvement in cognitive performance demonstrated by treatment with SAGE-718 could therefore provide meaningful clinical benefit to a vast majority of patients. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


•Aaron Koenig is an employee of Sage Therapeutics, Inc., and may hold stock and/or stock options.
•The LUMINARY and LIGHTWAVE studies are sponsored by Sage Therapeutics, Inc.
•SAGE‐718 is an investigational drug and is not approved by the US Food and Drug Administration or any other regulatory agency as safe and effective for any use.